WO2000028090A3 - Diagnostic assay for cancer - Google Patents
Diagnostic assay for cancer Download PDFInfo
- Publication number
- WO2000028090A3 WO2000028090A3 PCT/US1999/027005 US9927005W WO0028090A3 WO 2000028090 A3 WO2000028090 A3 WO 2000028090A3 US 9927005 W US9927005 W US 9927005W WO 0028090 A3 WO0028090 A3 WO 0028090A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- diagnostic assay
- glioblastoma
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU17240/00A AU1724000A (en) | 1998-11-12 | 1999-11-12 | Diagnostic assay for cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10812098P | 1998-11-12 | 1998-11-12 | |
US60/108,120 | 1998-11-12 | ||
US14564099P | 1999-07-27 | 1999-07-27 | |
US60/145,640 | 1999-07-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000028090A2 WO2000028090A2 (en) | 2000-05-18 |
WO2000028090A3 true WO2000028090A3 (en) | 2000-11-16 |
Family
ID=26805545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/027005 WO2000028090A2 (en) | 1998-11-12 | 1999-11-12 | Diagnostic assay for cancer |
Country Status (3)
Country | Link |
---|---|
US (3) | US6194158B1 (en) |
AU (1) | AU1724000A (en) |
WO (1) | WO2000028090A2 (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030165888A1 (en) * | 2001-07-18 | 2003-09-04 | Brown Bob D. | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes |
US6518017B1 (en) * | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
AU777499B2 (en) * | 1999-04-08 | 2004-10-21 | Gen-Probe Incorporated | Antisense oligonucleotides comprising universal and/or degenerate bases |
WO2001036685A2 (en) * | 1999-11-17 | 2001-05-25 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
US6589783B2 (en) * | 2000-04-13 | 2003-07-08 | Novagen, Inc. | Multiple host expression vector |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US20060259251A1 (en) * | 2000-09-08 | 2006-11-16 | Affymetrix, Inc. | Computer software products for associating gene expression with genetic variations |
IL155450A0 (en) * | 2000-10-20 | 2003-11-23 | Expression Diagnostics Inc | Leukocyte expression profiling |
WO2002040716A2 (en) * | 2000-11-16 | 2002-05-23 | Cemines, Llc | Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease |
US7026121B1 (en) * | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
WO2003002977A1 (en) * | 2001-06-29 | 2003-01-09 | Protea Biosciences, Inc. | Specimen-linked g protein coupled receptor database |
AU2002318437A1 (en) * | 2001-06-29 | 2003-03-03 | Clinomics Biosciences, Inc. | Evaluating neuropsychiatric diseases using a specimen-linked database |
US20070042360A1 (en) * | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
CA2459219A1 (en) * | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
US7291456B2 (en) | 2002-01-24 | 2007-11-06 | The Regents Of The University Of California | Method for determining differences in molecular interactions and for screening a combinatorial library |
WO2003105773A2 (en) * | 2002-06-01 | 2003-12-24 | Oregon Health & Science University | Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets: |
JP2006512924A (en) * | 2002-08-15 | 2006-04-20 | ジェンザイム・コーポレーション | Brain endothelial cell expression pattern |
US7892745B2 (en) * | 2003-04-24 | 2011-02-22 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
JP2006525027A (en) | 2003-05-01 | 2006-11-09 | ジェン−プロウブ インコーポレイテッド | Oligonucleotides containing molecular switches |
WO2006029184A2 (en) * | 2004-09-08 | 2006-03-16 | Expression Diagnostics, Inc. | Genes useful for diagnosing and monitoring inflammation related disorders |
WO2006122295A2 (en) * | 2005-05-11 | 2006-11-16 | Expression Diagnostics, Inc. | Methods of monitoring functional status of transplants using gene panels |
WO2007047907A2 (en) * | 2005-10-14 | 2007-04-26 | The Regents Of The University Of Michigan | Dek protein compositions and methods of using the same |
AU2007309726A1 (en) * | 2006-04-07 | 2008-05-02 | Xdx, Inc. | Steroid responsive nucleic acid expression and prediction of disease activity |
US7993832B2 (en) * | 2006-08-14 | 2011-08-09 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders |
WO2008140484A2 (en) * | 2006-11-09 | 2008-11-20 | Xdx, Inc. | Methods for diagnosing and monitoring the status of systemic lupus erythematosus |
WO2009039390A2 (en) * | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
AU2009293164B2 (en) | 2008-09-18 | 2015-07-09 | Northwestern University | NMDA receptor modulators and uses thereof |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
KR101692275B1 (en) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | Secondary structure stabilized nmda receptor modulators and uses thereof |
AU2011215704B2 (en) | 2010-02-11 | 2015-07-23 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
BR112015018095A2 (en) | 2013-01-29 | 2017-07-18 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
ES2935352T3 (en) | 2013-01-29 | 2023-03-06 | Aptinyx Inc | Spiro-lactam NMDA receptor modulators and their uses |
SG11201505934XA (en) | 2013-01-29 | 2015-09-29 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
WO2014120784A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
ES2618421T3 (en) | 2013-01-29 | 2017-06-21 | Aptinyx Inc. | NMDA receptor spiro-lactam modulators and uses thereof |
KR101592305B1 (en) * | 2013-10-08 | 2016-02-05 | 사회복지법인 삼성생명공익재단 | Limiting Dilution Assay for Screening of Patient-specific Anti-cancer Agents |
US9459201B2 (en) | 2014-09-29 | 2016-10-04 | Zyomed Corp. | Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing |
US10724091B1 (en) | 2015-02-10 | 2020-07-28 | National Technology & Engineering Solutions Of Sandia, Llc | Endpoint detection of amplified nucleic acids |
US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
PE20190174A1 (en) | 2016-05-19 | 2019-02-01 | Aptinyx Inc | SPIRO-LACTAM N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND USES OF THEM |
AU2017306152A1 (en) | 2016-08-01 | 2019-01-31 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
PE20190501A1 (en) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | NMDA ESPIRO-LACTAM MODULATORS AND METHODS OF USE OF THE SAME |
EA201990425A1 (en) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | SPIRO-LACTAM AND BIS-SPIRO-LACTAM MODULATORS OF THE NMDA RECEPTOR AND THEIR APPLICATION |
US10961189B2 (en) | 2016-08-01 | 2021-03-30 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
WO2018026782A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
US11578072B2 (en) | 2018-01-31 | 2023-02-14 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013877A1 (en) * | 1995-10-12 | 1997-04-17 | Lynx Therapeutics, Inc. | Measurement of gene expression profiles in toxicity determination |
WO1997027317A1 (en) * | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Nucleic acid analysis techniques |
WO1998035041A1 (en) * | 1997-02-06 | 1998-08-13 | Incyte Pharmaceuticals, Inc. | Human lea-motif developmental protein |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5599696A (en) | 1989-10-17 | 1997-02-04 | California Institute Of Technology | Method of preparing nucleic acids having an undefined nucleotide sequence amplification |
US5104792A (en) | 1989-12-21 | 1992-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method for amplifying unknown nucleic acid sequences |
US5470970A (en) | 1991-02-28 | 1995-11-28 | Dana-Farber Cancer Institute, Inc. | Maspin, a serpin with tumor suppresing activity |
ATE231920T1 (en) | 1992-03-11 | 2003-02-15 | Dana Farber Cancer Inst Inc | METHOD TO CLONE MRNA |
US5262311A (en) | 1992-03-11 | 1993-11-16 | Dana-Farber Cancer Institute, Inc. | Methods to clone polyA mRNA |
US5744300A (en) | 1993-03-24 | 1998-04-28 | Geron Corporation | Methods and reagents for the identification and regulation of senescence-related genes |
US5580726A (en) | 1994-04-29 | 1996-12-03 | Geron Corporation | Method and Kit for enhanced differential display |
US5744306A (en) | 1993-04-19 | 1998-04-28 | Emory University | Methods for nucleic acid detection, sequencing, and cloning using exonuclease |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
US5459037A (en) | 1993-11-12 | 1995-10-17 | The Scripps Research Institute | Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations |
US5654419A (en) | 1994-02-01 | 1997-08-05 | The Regents Of The University Of California | Fluorescent labels and their use in separations |
US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
US5861293A (en) | 1994-06-13 | 1999-01-19 | Banyu Pharmaceutical Co., Ltd. | Gene encoding glycosyltransferase and its uses |
RU2111254C1 (en) | 1994-07-11 | 1998-05-20 | Институт молекулярной биологии им.В.А.Энгельгардта РАН | Method of detection of differentially expressing template rnas and cloning the corresponding cdna fragments |
US5710000A (en) | 1994-09-16 | 1998-01-20 | Affymetrix, Inc. | Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5922601A (en) | 1995-01-19 | 1999-07-13 | Biotransplant, Inc. | High efficiency gene trap selection of regulated genetic loci |
US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
US5753439A (en) | 1995-05-19 | 1998-05-19 | Trustees Of Boston University | Nucleic acid detection methods |
US5759776A (en) | 1995-06-05 | 1998-06-02 | California Pacific Medical Center | Targets for breast cancer diagnosis and treatment |
US5700644A (en) | 1995-06-07 | 1997-12-23 | Wisconsin Alumni Research Foundation | Identification of differentially expressed genes |
US5712126A (en) | 1995-08-01 | 1998-01-27 | Yale University | Analysis of gene expression by display of 3-end restriction fragments of CDNA |
US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
US5776683A (en) | 1996-07-11 | 1998-07-07 | California Pacific Medical Center | Methods for identifying genes amplified in cancer cells |
US5968784A (en) | 1997-01-15 | 1999-10-19 | Chugai Pharmaceutical Co., Ltd. | Method for analyzing quantitative expression of genes |
US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
-
1999
- 1999-11-12 WO PCT/US1999/027005 patent/WO2000028090A2/en active Application Filing
- 1999-11-12 AU AU17240/00A patent/AU1724000A/en not_active Abandoned
- 1999-11-12 US US09/438,938 patent/US6194158B1/en not_active Expired - Fee Related
-
2000
- 2000-09-25 US US09/668,885 patent/US6440676B1/en not_active Expired - Fee Related
-
2002
- 2002-07-03 US US10/190,377 patent/US20030175734A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013877A1 (en) * | 1995-10-12 | 1997-04-17 | Lynx Therapeutics, Inc. | Measurement of gene expression profiles in toxicity determination |
WO1997027317A1 (en) * | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Nucleic acid analysis techniques |
WO1998035041A1 (en) * | 1997-02-06 | 1998-08-13 | Incyte Pharmaceuticals, Inc. | Human lea-motif developmental protein |
Non-Patent Citations (3)
Title |
---|
DATABASE EMBL 29 October 1998 (1998-10-29), INCYTE PAHRM INC.: "human LEA motif developmental protein coding sequence", XP002141424 * |
DATABASE EMBL embl heidelberg; 1 June 1999 (1999-06-01), LIN W.C.: "homo sapiens CGI-106 protein mRNA", XP002141423 * |
YAMAGUCHI F. ET AL.,: "Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas", PROC. NATL. ACAD. SCI. USA, vol. 91, - January 1994 (1994-01-01), pages 484 - 488, XP002141422 * |
Also Published As
Publication number | Publication date |
---|---|
AU1724000A (en) | 2000-05-29 |
WO2000028090A2 (en) | 2000-05-18 |
US6440676B1 (en) | 2002-08-27 |
US20030175734A1 (en) | 2003-09-18 |
US6194158B1 (en) | 2001-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000028090A3 (en) | Diagnostic assay for cancer | |
WO2001036685A3 (en) | Differential gene expression in cancer | |
MXPA03003151A (en) | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer. | |
WO2002080754A3 (en) | Methods for using annexin for detecting cell death in vivo and treating associated conditions | |
WO2003008583A3 (en) | Novel compositions and methods for cancer | |
AU2001231199A1 (en) | Compositions and methods for the early diagnosis of ovarian cancer | |
WO2003066802A3 (en) | Gene expression analysis using nicking agents | |
WO2001072962A3 (en) | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
AU2001265296A1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
AU2001249549A1 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
WO2004050707A3 (en) | Tumor-specific recognition molecules | |
WO2003048301A3 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
WO2001075178A3 (en) | Methods for identifying peptide aptamers capable of altering a cell phenotype | |
WO2002030465A3 (en) | Compositions that inhibit proliferation of cancer cells | |
AU4224599A (en) | Anti-prostate cancer vaccines, and methods of making, using and evaluating the same | |
WO1999020747A3 (en) | HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS | |
WO2003045230A3 (en) | Novel compositions and methods for cancer | |
WO2003057146A3 (en) | Novel compositions and methods for cancer | |
WO1997029199A3 (en) | Prostate specific antigen peptides and uses thereof | |
WO2001042792A3 (en) | Diagnosis of cervical cancer using marker proteins | |
WO2001009384A3 (en) | Serial analysis of genetic alterations | |
WO2003053224A3 (en) | Novel compositions and methods for cancer | |
WO2005058251A3 (en) | Hla-dr-specific antibodies, compositions and methods | |
AU3896899A (en) | Compositions for the treatment of tumors, and uses thereof | |
WO2003035837A3 (en) | Novel compositions and methods for cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 17240 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |